Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Martín M, Carrasco E, Rodríguez-Lescure Á, Andrés R, Servitja S, Antón A, Ruiz-Borrego M, Bermejo B, Guerrero Á, Ramos M, Santaballa A, Muñoz M, Cruz J, Lopez-Tarruella S, Chacón JI, Álvarez I, Martínez P, Miralles JJ, Polonio Ó, Jara C, Aguiar-Bujanda D. Martín M, et al. Among authors: aguiar bujanda d. Breast Cancer Res Treat. 2023 Sep;201(2):151-159. doi: 10.1007/s10549-023-07002-1. Epub 2023 Jun 20. Breast Cancer Res Treat. 2023. PMID: 37338729 Free PMC article. Review.
Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial.
Clavo B, Martínez-Sánchez G, Rodríguez-Esparragón F, Rodríguez-Abreu D, Galván S, Aguiar-Bujanda D, Díaz-Garrido JA, Cañas S, Torres-Mata LB, Fabelo H, Téllez T, Santana-Rodríguez N, Fernández-Pérez L, Marrero-Callico G. Clavo B, et al. Among authors: aguiar bujanda d. Int J Mol Sci. 2021 Mar 10;22(6):2802. doi: 10.3390/ijms22062802. Int J Mol Sci. 2021. PMID: 33802143 Free PMC article. Review.
Modulation of Oxidative Stress by Ozone Therapy in the Prevention and Treatment of Chemotherapy-Induced Toxicity: Review and Prospects.
Clavo B, Rodríguez-Esparragón F, Rodríguez-Abreu D, Martínez-Sánchez G, Llontop P, Aguiar-Bujanda D, Fernández-Pérez L, Santana-Rodríguez N. Clavo B, et al. Among authors: aguiar bujanda d. Antioxidants (Basel). 2019 Nov 26;8(12):588. doi: 10.3390/antiox8120588. Antioxidants (Basel). 2019. PMID: 31779159 Free PMC article. Review.
Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer.
Ortega-Granados AL, Artal-Cortes Á, Aguiar-Bujanda D, Oramas J, Fírvida JL, DE Castro J, Fuentes JC, Gordo R, Galán R, Trigo J; ASPET Study Investigators. Ortega-Granados AL, et al. Among authors: aguiar bujanda d. Anticancer Res. 2019 Mar;39(3):1317-1328. doi: 10.21873/anticanres.13244. Anticancer Res. 2019. PMID: 30842164
Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
Aguiar-Bujanda D, Dueñas-Comino A, Saura-Grau S, Ros-Sanjuan L, Blanco-Sanchez MJ, Hernandez-Sosa M, Mori-De Santiago M, Galvan-Ruiz S, Lorenzo-Barreto JE, Vargas-Prado AM, Bohn-Sarmiento U. Aguiar-Bujanda D, et al. Oncol Res Treat. 2018;41(12):755-761. doi: 10.1159/000492344. Epub 2018 Nov 13. Oncol Res Treat. 2018. PMID: 30419558
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group.
Franco Pérez F, Lavernia J, Aguiar-Bujanda D, Miramón J, Gumá J, Álvarez R, Gómez-Codina J, Arroyo FG, Llanos M, Marin M, Alfaro J, Quero C, Delgado M, Nogales E, Menarguez F, Martinez N, Torrente M, Royuela A, Abreu D, Provencio M. Franco Pérez F, et al. Among authors: aguiar bujanda d. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):186-191. doi: 10.1016/j.clml.2016.09.004. Epub 2016 Sep 17. Clin Lymphoma Myeloma Leuk. 2017. PMID: 27847267 Free article.
35 results